| NCT ID | NCT03527420 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Illinois at Chicago |
| Condition | Obesity |
| Study Type | INTERVENTIONAL |
| Enrollment | 80 participants |
| Start Date | 2019-10-11 |
| Primary Completion | 2026-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 80 participants in total. It began in 2019-10-11 with a primary completion date of 2026-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The main objective is to examine DNA hypomethylation as an underlying mechanism for the increased production of inflammatory cytokines and the impaired vascular function in obese individuals and as a potential target for nonpharmacological preventive/therapeutic interventions such as aerobic exercise.
Eligibility Criteria
Inclusion Criteria: * BMI ≥ 35 kg/m2 * Between ages 18-50 years * Not pregnant * Approved for a bariatric surgery Exclusion Criteria: * To avoid confounding from other inflammatory conditions individuals with current cancer, heart, kidney or liver disease, gallbladder disease or acute or chronic inflammatory diseases (including rheumatoid arthritis, lupus and other autoimmune diseases and genetic diseases) will be excluded * Pregnant women will be excluded, as they will not be eligible for bariatric surgery * Current smokers * Currently abusing alcohol or drugs
Contact & Investigator
Abeer Mohamed, MD, PhD
PRINCIPAL INVESTIGATOR
University of Illinois at Chicago
Frequently Asked Questions
Who can join the NCT03527420 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 50 Years, studying Obesity. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03527420 currently recruiting?
Yes, NCT03527420 is actively recruiting participants. Contact the research team at amahmo4@uic.edu for enrollment information.
Where is the NCT03527420 trial being conducted?
This trial is being conducted at Chicago, United States.
Who is sponsoring the NCT03527420 clinical trial?
NCT03527420 is sponsored by University of Illinois at Chicago. The principal investigator is Abeer Mohamed, MD, PhD at University of Illinois at Chicago. The trial plans to enroll 80 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.